What To Know About RBC Capital's Downgrade of Sangamo Therapeutics
Portfolio Pulse from Benzinga Insights
RBC Capital has downgraded its rating of Sangamo Therapeutics (NASDAQ:SGMO) to Sector Perform with a new price target of $2.00, down from $6.00. Despite this, shares of Sangamo Therapeutics are trading up 0.0% over the last 24 hours, at $0.46 per share. A move to $2.00 would account for a 334.78% increase from the current share price.
November 03, 2023 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
RBC Capital has downgraded Sangamo Therapeutics and lowered its price target. However, the new target still represents a significant potential upside.
The downgrade by RBC Capital might initially seem negative, but the new price target of $2.00 is significantly higher than the current trading price of $0.46. This suggests that despite the downgrade, RBC Capital still sees potential for significant growth in Sangamo Therapeutics' stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100